LAVA Therapeutics BV

LAVA Therapeutics N.V. a clinical-stage immuno-oncology company focuses on developing cancer treatments. The company through its Gammabody platform develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051 which is in Phase 1/2a clinical trial for blood cancers including chronic lymphocytic leukemia multiple myeloma and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates which include LAVA-1223 which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors as well as LAVA-1266 and LAVA-1278 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht the Netherlands.